The Centers for Medicare & Medicaid Services (CMS) is calling its pilot scheme the GENErating cost Reductions fOr US Medicaid or GENEROUS model, and is now seeking companies that wish to take part.

Metsera said it expects the Pfizer deal to close promptly after a stockholder meeting scheduled for this coming Thursday ...

Pfizer is leaving no stone unturned in its efforts to prevent Novo Nordisk from stealing off with Metsera, the weight-loss therapy developer it is hoping to acquire in a deal worth up to $7.3 billion.

Thousands of people from some of Scotland's most deprived communities will get access to Novo Nordisk's GLP-1 agonist Wegovy in a study looking at the real-world impact of weight-loss medicines. The ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that are ...

The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 ...

Eisai has already reached settlement agreements with two other companies seeking to market Lenvima generics in the US – Sun ...

The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 ...